Challenges in  hemoglobinopathy control programs: Insights from Türkiye

Y Yesim Aydinok (1Ege University School of Medicine, Pediatric Hematology and Oncology, Izmir, Türkiye) A Alphan Kupesiz (2Akdeniz University School of Medicine, Pediatric Hematology and Oncology, Antalya, Türkiye) B Burcak Tatli Gunes (4SBU Tepecik Training and Research Hospital, Pediatric Hematology and Oncology, Izmir, Türkiye) A Ayse Gonca Kacar (4Basaksehir Cam and Sakura City Hospital, Pediatric Hematology and Oncology, Istanbul, Türkiye) D Dilber Talia Ileri (5Ankara University School of Medicine, Pediatric Hematology and Oncology, Ankara, Türkiye) H Hamiyet Hekimci Ozdemir (6Dr. Behcet Uz Children’s Hospital, Pediatric Hematology and Oncology, Izmir, Türkiye) A Ayca Yozgat (7Ankara Bilkent City Hospital, Pediatric Hematology and Oncology, Ankara, Türkiye) M Mehtap Ertekin (8Sanliurfa Training and Research Hospital, Pediatric Hematology and Oncology, Sanliurfa, Türkiye) H Huseyin Tokgoz (14Necmettin Erbakan University School of Medicine, Pediatric Hematology and Oncology, Konya, Türkiye) M Melike Evim (10Uludag University School of Medicine, Pediatric Hematology and Oncology, Bursa, Türkiye) E Elif Kazanci (11Bursa Yuksek Ihtisas Training and Research Hospital, Pediatric Hematology and Oncology, Bursa, Türkiye) A Ayse Simsek (12Konya City Hospital, Hematology, Konya, Türkiye) S Sule Unal (9Hacettepe University School of Medicine, Pediatric Hematology and Oncology, Ankara, Türkiye) S Selma Ünal A Alper Ozcan (8Erciyes University School of Medicine, Pediatric Hematology and Oncology, Kayseri, Türkiye) S Suheyla Ocak (16Istanbul University, Cerrahpasa School of Medicine, Pediatric Hematology and Oncology, Istanbul, Türkiye) M Mustafa Cemaloglu (17Hatay State Hospital, Pediatric Hematology and Oncology, Hatay, Türkiye) S Sultan Aydın (18SBU Antaly Training and Research Hospital, Hematology, Antalya, Türkiye) N Nazan Sarper (24Kocaeli University School of Medicine, Pediatric Hematology and Oncology, Kocaeli, Türkiye) C Can Acipayam (22Kahramanmaras Sutcu Imam School of Medicine, Pediatric Hematology and Oncology, Kahramanmaras, Türkiye) O Ozcan Bor (17Osmangazi University School of Medicine, Pediatric Hematology and Oncology, Eskisehir, Türkiye) H Hale Oren (22Dokuz Eylul University School of Medicine, Pediatric Hematology and Oncology, Izmir, Türkiye) N Nihal Karadas F Funda Kupesiz (6Akdeniz University Faculty of Medicine, Pediatric Hematology, Antalya, Türkiye) Y Yesim Yigit (24Balikesir Ataturk City Hospital, Pediatric Hematology and Oncology, Balikesir, Türkiye) N Nihal Boz (25Gaziantep Cengiz Gokcek Obstetrics and Children’s Hospital, Pediatric Hematology and Oncology, Gaziantep, Türkiye) A Ahmet Koc S Sinan Akbayram (27Gaziantep University School of Medicine, Pediatric Hematology and Oncology, Gaziantep, Türkiye) M Mehmet Fatih Orhan M Murat Soker (29Dicle University School of Medicine, Pediatric Hematology and Oncology, Diyarbakır, Türkiye) D Defne Ay Tuncel (30Adana City Training and Research Hospital, Pediatric Hematology and Oncology, Adana, Türkiye) M Mediha Akcan (31Adnan Menderes University School of Medicine, Pediatric Hematology and Oncology, Aydin, Türkiye) N Nurettin Okur (32Diyarbakir Children’s Hospital, Pediatric Hematology and Oncology, Diyarbakır, Türkiye) C Canan Albayrak O Ozlem Gul Kirkas (34Bursa Dortcelik State Hospital, Pediatric Hematology and Oncology, Bursa, Türkiye) F Fatih Azik (35Sitki Kocman University School of Medicine, Pediatric Hematology and Oncology, Mugla, Türkiye) T Tuba Nur Tahtakesen Gucer (36Mardin Training and Research Hospital, Pediatric Hematology and Oncology, Mardin, Türkiye) K Kamuran Karaman (37Yuzuncuyil University School of Medicine, Pediatric Hematology and Oncology, Van, Türkiye) E Emine Turkkan (38Ok Meydani Education and Research Hospital, Pediatric Hematology and Oncology, Istanbul, Türkiye) S Sifa Sahin (39Batman Education and Research Hospital, Pediatric Hematology and Oncology, Batman, Türkiye) A Ali Fettah (40Dr Sami Ulus Training and Research Hospital, Pediatric Hematology and Oncology, Ankara, Türkiye) A Aylin Canbolat (41Istanbul Medeniyet University , Goztepe Training and Research Hospital, Pediatric Hematology and Oncology, Istanbul, Türkiye) A Arzu Akyay (42Inonu University School of Medicine, Pediatric Hematology and Oncology, Malatya, Türkiye) H Huseyin Gulen (43Celal Bayar University School of Medicine, Pediatric Hematology and Oncology, Manisa, Türkiye) M Meryem Albayrak (44Kırıkkale University School of Medicine, Pediatric Hematology and Oncology, Kırıkkale, Türkiye) Y Yilmaz Ay (45Pamukkale University School of Medicine, Pediatric Hematology and Oncology, Denizli, Türkiye) Z Zeynep Karakas (2Istanbul University, Istanbul School of Medicine, Pediatric Hematology and Oncology, Istanbul, Türkiye)

Abstract

Abstract Introduction Hemoglobinopathies are among the most common inherited diseases worldwide. Countries with a high prevalence of carriers have implemented population-based premarital screening to prevent the disease. In Turkey, a national hemoglobinopathy control program (NHCP) was officially launched in 2003. This program includes carrier screening, which is preceded by genetic counseling, public education, and prenatal diagnosis (PND). However, a study conducted among registered patients in the National Hemoglobinopathy Registry (NHR) of the Turkish Hematology Association between 2011 and 2015 (Turk J Hematol 2018;35:12-18) did not show a consistent decline in the number of affected births over time in Turkey. Since those times, Turkey has experienced a significant influx of over 3 million Syrian migrants. Furthermore, a substantial number of patients of all ages have been added to the NHR over the last decade. This study examines the changing trends in the births of affected children in Turkey, utilizing data from the recent NHR database. Methods The demographics of patients included in the NHR were evaluated. We collected data on patients born in each year from 2000 onward, noting that those born since 2005 represent the affected births following the implementation of NHCP. Patients of other nationalities were evaluated separately, as it remains unclear whether they were born in Turkey. All births with hemoglobinopathies over 25 years, between 2000 and 2024, were evaluated by dividing the time into 5-year periods, with the first 5 years representing the period before the establishment of the NHCP. The latter data was projected for the following five-year periods between 2005 and 2024 and then compared to the actual data from the same period. The information regarding premarital screening, genetic counseling, and PND was collected from the parents. Results The NHR includes a total of 5,075 patients, comprising 4,255 with thalassemia and 820 with sickle cell disorders. Among these patients, 372 are immigrants. Notably, 38% of the registered Turkish citizen patients (n = 1,784) were born between 2005 and 2024, and 1,629 of those had thalassemia. Between 2000 and 2004, a total of 718 births were recorded. The average number of births each year was 144 ± 6 (median 146). Over the following five-year periods, a gradual decline in the average number of births was observed as; 2005-2009, 133 ± 12 (median 142), 2010-2014, 113 ± 6 (median 114), 2015-2019, 85 ± 7 (median 88), and 2020-2024, 26 ± 11 (median 28). The significant decline in the final five-year period requires caution, as not all pediatric centers have updated their registries between 2020 and 2024. In contrast, out of 372 patients from other nationalities, 308 were born between 2005 and 2024, with a gradual increase in births at five-year intervals, peaking with the highest number (n = 114) during the period from 2015 to 2019. Only 32% of parents of patients born after 2004 underwent premarital screening. The screening rate was much lower among migrant couples, at just 5%. Of those who were screened, 60% received information about being at-risk couples to have affected children. However, only 30.5% of these couples opted for prenatal diagnosis (PND), yet went on to have their babies, even though the law permitted the termination of pregnancies involving affected babies. Additionally, 21% of parents reported receiving inaccurate results for their carrier status, while 19% did not receive any information about the screening at all. ConclusionsAn analysis of the registry reveals that the NHCP has achieved a 37% reduction in the number of births with hemoglobinopathies over the past 20 years, demonstrating a consistent and gradual decline since its inception. However, it is essential to address the program's shortcomings that may hinder even greater success. Additionally, an urgent strategy is needed for the migrated population of reproductive age, taking into account the societal values of that community.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 4693-4693
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (47)

Y

Yesim Aydinok

1Ege University School of Medicine, Pediatric Hematology and Oncology, Izmir, Türkiye

A

Alphan Kupesiz

2Akdeniz University School of Medicine, Pediatric Hematology and Oncology, Antalya, Türkiye

B

Burcak Tatli Gunes

4SBU Tepecik Training and Research Hospital, Pediatric Hematology and Oncology, Izmir, Türkiye

A

Ayse Gonca Kacar

4Basaksehir Cam and Sakura City Hospital, Pediatric Hematology and Oncology, Istanbul, Türkiye

D

Dilber Talia Ileri

5Ankara University School of Medicine, Pediatric Hematology and Oncology, Ankara, Türkiye

H

Hamiyet Hekimci Ozdemir

6Dr. Behcet Uz Children’s Hospital, Pediatric Hematology and Oncology, Izmir, Türkiye

A

Ayca Yozgat

7Ankara Bilkent City Hospital, Pediatric Hematology and Oncology, Ankara, Türkiye

M

Mehtap Ertekin

8Sanliurfa Training and Research Hospital, Pediatric Hematology and Oncology, Sanliurfa, Türkiye

H

Huseyin Tokgoz

14Necmettin Erbakan University School of Medicine, Pediatric Hematology and Oncology, Konya, Türkiye

M

Melike Evim

10Uludag University School of Medicine, Pediatric Hematology and Oncology, Bursa, Türkiye

E

Elif Kazanci

11Bursa Yuksek Ihtisas Training and Research Hospital, Pediatric Hematology and Oncology, Bursa, Türkiye

A

Ayse Simsek

12Konya City Hospital, Hematology, Konya, Türkiye

S

Sule Unal

9Hacettepe University School of Medicine, Pediatric Hematology and Oncology, Ankara, Türkiye

S

Selma Ünal

A

Alper Ozcan

8Erciyes University School of Medicine, Pediatric Hematology and Oncology, Kayseri, Türkiye

S

Suheyla Ocak

16Istanbul University, Cerrahpasa School of Medicine, Pediatric Hematology and Oncology, Istanbul, Türkiye

M

Mustafa Cemaloglu

17Hatay State Hospital, Pediatric Hematology and Oncology, Hatay, Türkiye

S

Sultan Aydın

18SBU Antaly Training and Research Hospital, Hematology, Antalya, Türkiye

N

Nazan Sarper

24Kocaeli University School of Medicine, Pediatric Hematology and Oncology, Kocaeli, Türkiye

C

Can Acipayam

22Kahramanmaras Sutcu Imam School of Medicine, Pediatric Hematology and Oncology, Kahramanmaras, Türkiye

O

Ozcan Bor

17Osmangazi University School of Medicine, Pediatric Hematology and Oncology, Eskisehir, Türkiye

H

Hale Oren

22Dokuz Eylul University School of Medicine, Pediatric Hematology and Oncology, Izmir, Türkiye

N

Nihal Karadas

F

Funda Kupesiz

6Akdeniz University Faculty of Medicine, Pediatric Hematology, Antalya, Türkiye

Y

Yesim Yigit

24Balikesir Ataturk City Hospital, Pediatric Hematology and Oncology, Balikesir, Türkiye

N

Nihal Boz

25Gaziantep Cengiz Gokcek Obstetrics and Children’s Hospital, Pediatric Hematology and Oncology, Gaziantep, Türkiye

A

Ahmet Koc

S

Sinan Akbayram

27Gaziantep University School of Medicine, Pediatric Hematology and Oncology, Gaziantep, Türkiye

M

Mehmet Fatih Orhan

M

Murat Soker

29Dicle University School of Medicine, Pediatric Hematology and Oncology, Diyarbakır, Türkiye

D

Defne Ay Tuncel

30Adana City Training and Research Hospital, Pediatric Hematology and Oncology, Adana, Türkiye

M

Mediha Akcan

31Adnan Menderes University School of Medicine, Pediatric Hematology and Oncology, Aydin, Türkiye

N

Nurettin Okur

32Diyarbakir Children’s Hospital, Pediatric Hematology and Oncology, Diyarbakır, Türkiye

C

Canan Albayrak

O

Ozlem Gul Kirkas

34Bursa Dortcelik State Hospital, Pediatric Hematology and Oncology, Bursa, Türkiye

F

Fatih Azik

35Sitki Kocman University School of Medicine, Pediatric Hematology and Oncology, Mugla, Türkiye

T

Tuba Nur Tahtakesen Gucer

36Mardin Training and Research Hospital, Pediatric Hematology and Oncology, Mardin, Türkiye

K

Kamuran Karaman

37Yuzuncuyil University School of Medicine, Pediatric Hematology and Oncology, Van, Türkiye

E

Emine Turkkan

38Ok Meydani Education and Research Hospital, Pediatric Hematology and Oncology, Istanbul, Türkiye

S

Sifa Sahin

39Batman Education and Research Hospital, Pediatric Hematology and Oncology, Batman, Türkiye

A

Ali Fettah

40Dr Sami Ulus Training and Research Hospital, Pediatric Hematology and Oncology, Ankara, Türkiye

A

Aylin Canbolat

41Istanbul Medeniyet University , Goztepe Training and Research Hospital, Pediatric Hematology and Oncology, Istanbul, Türkiye

A

Arzu Akyay

42Inonu University School of Medicine, Pediatric Hematology and Oncology, Malatya, Türkiye

H

Huseyin Gulen

43Celal Bayar University School of Medicine, Pediatric Hematology and Oncology, Manisa, Türkiye

M

Meryem Albayrak

44Kırıkkale University School of Medicine, Pediatric Hematology and Oncology, Kırıkkale, Türkiye

Y

Yilmaz Ay

45Pamukkale University School of Medicine, Pediatric Hematology and Oncology, Denizli, Türkiye

Z

Zeynep Karakas

2Istanbul University, Istanbul School of Medicine, Pediatric Hematology and Oncology, Istanbul, Türkiye